This is a pilot, open-label study of raltegravir and maraviroc in combination for the
treatment of antiretroviral naïve patients. The study will enroll 7 antiretroviral naïve
patients with CD4 counts ≥ 350 and viral loads > 5,000. The subjects will be followed for 48
weeks. The combination of these two agents has the potential to be a potent regimen with
minimal metabolic complications. However, they have not been studied in combination
previously.
This pilot study proposes to evaluate this combination in antiretroviral naïve patients to
document the safety and efficacy of this combination in order to provide clinicians with a
treatment regimen that minimizes the risk of metabolic complications.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore